Literature DB >> 16389375

Glycoprotein IIb/IIIa receptor antagonists: a review of the pivotal trials.

C Gurk-Turner1.   

Abstract

Year:  2000        PMID： 16389375      PMCID： PMC1312303          DOI： 10.1080/08998280.2000.11927665

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  10 in total

1.  Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.

Authors: 
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

2.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

Authors: 
Journal:  N Engl J Med       Date:  1997-06-12       Impact factor: 91.245

3.  A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

4.  Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

5.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

6.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

7.  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

8.  Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.

Authors:  J E Tcheng; R A Harrington; K Kottke-Marchant; N S Kleiman; S G Ellis; D J Kereiakes; M J Mick; F I Navetta; J E Smith; S J Worley
Journal:  Circulation       Date:  1995-04-15       Impact factor: 29.690

9.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.